Avacta: pre|CISION prospects build
Avacta is approaching a defining period, with the imminent Phase I start of its second asset AVA6103 (FAP-EXd), a sustained release pre|CISION-exatecan conjugate. Initial data by year-end, as well as first breast cancer data for lead asset faridoxorubicin (AVA6000, FAP-Dox) could crystallise partnering interest. The utility, and value, of the pre|CISION platform is becoming clearer as growing preclinical and clinical data confirm its ability to improve the therapeutic index of many highly potent yet systemically toxic oncology drugs. Advances in pre|CISION chemistry, employing capping groups and novel linkers, have the potential to expand applicability of this technology to a wider range of payloads and cancer types. Newly unveiled novel dual payload PDC platform AVA6207 exemplifies Avacta’s skillset and ambition. Pipeline progress into the clinic and successful clinical results over the next 24 months should provide multiple value-inflection points. We value Avacta at £468m, or 106p/share.Avacta Group is a biotechnology company that is developing biotherapeutics and reagents based on its proprietary Affimer technology, an engineered alternative to antibodies. Affimer® reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a range of applications where antibodies and aptamers have limitations. Co. has two operating segments: Life Sciences, which provides custom Affimers for reagents and diagnostics, drug and biomarker discovery in biotech research and development; and Animal Health, which provides tools and contract services to assist diagnosis of conditions in animals to enable treatment for veterinarians.
We are experienced healthcare and life sciences analysts providing the highest quality service to companies in these sectors and to investors. We have expertise in the fields of the biotech, medtech , specialty pharma and consumer health sectors.
The old-fashioned values of the City enabled London to become a global financial centre, and we pride ourselves for our integrity and professionalism, where our word is our bond. This applies to our research, and all interactions with companies, the buyside and other partners.
We also firmly believe that by putting our clients first, we create long term value for all stakeholders.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.